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Background: Although many pathological changes have been associated with ischemic
heart disease (IHD), molecular-level alterations specific to the ischemic myocardium and
their potential to reflect disease severity or therapeutic outcome remain unclear. Currently,
diagnosis occurs relatively late and evaluating disease severity is largely based on clinical
symptoms, various imaging modalities, or the determination of risk factors. This study
aims to identify IHD-associated signature RNAs from the atrial myocardium and evaluate
their ability to reflect disease severity or cardiac surgery outcomes.
Methods and Results: We collected right atrial appendage (RAA) biopsies from 40
patients with invasive coronary angiography (ICA)-positive IHD undergoing coronary
artery bypass surgery and from 8 patients ICA-negative for IHD (non-IHD) undergoing
valvular surgery. Following RNA sequencing, RAA transcriptomes were analyzed against
429 donors from the GTEx project without cardiac disease. The IHD transcriptome
was characterized by repressed RNA expression in pathways for cell–cell contacts
and mitochondrial dysfunction. Increased expressions of the CSRNP3, FUT10, SHD,
NAV2-AS4, and hsa-mir-181 genes resulted in significance with the complexity of
coronary artery obstructions or correlated with a functional cardiac benefit from
bypass surgery.
Conclusions: Our results provide an atrial myocardium-focused insight into IHD
signature RNAs. The specific gene expression changes characterized here, pave the
way for future disease mechanism-based identification of biomarkers for early detection
and treatment of IHD.
Keywords: biomarkers, ischemia, chronic ischemic heart disease, cardiovascular surgery, atrial appendage,
differentially expressed genes
INTRODUCTION
The early diagnosis of ischemic heart disease (IHD) could facilitate the design of therapeutic
strategies and, thus, improve patient prognosis (1). To this end, IHD biomarkers which specifically
and sensitively correlate with disease severity are required (2). Currently, initial assessment of
IHD is largely based on the patient’s clinical symptoms, distinct electrocardiographic (ECG)
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alterations, and risk scoring. Diagnosis depends on cardiac
stress testing and radiographic evaluations of coronary
vessel obstructions or myocardial perfusion (3, 4). These are
supplemented with laboratory investigations (5). These surrogate
markers, however, do not directly reflect the myocardial
structure, metabolism, or inflammation (6). We propose that
the right atrial appendage (RAA), safely sampled during heart
surgery, can provide direct insight into the pathophysiological
myocardial changes manifesting in IHD. For the further
discovery of IHD biomarkers, it is crucial to understand these
changes and to utilize them for laying the rational pathology-
based groundwork in molecular detail. Toward this, we collected
48 RAA biopsies from patients with or without IHD, and
compared their RNA-sequenced (RNAseq) transcriptomes
to those from RAA biopsies from 429 donors without heart
disease available from the Genotype Tissue Expression (GTEx)
project. In doing so, we establish RAA as a feasible source for the
functional and metabolic characterization of cardiac ischemic
pathologies, and show that specific RAA gene expressions




This study was approved by the Operative Ethics Committee
of the Hospital District of Helsinki and Uusimaa (DNro
286/13/03/02/2012). The study was registered to the ISRCTN
registry (ISRCTN15411573). Before surgery, all patients provided
their written informed consent and received treatment adhering
to evidence-based clinical guidelines as routinely adopted by
healthcare centers.
Patients and Samples
For this study, we recruited a total of 54 patients scheduled
to undergo elective cardiac surgery between 2014 and 2015
at the Heart and Lung Center at Helsinki University Central
Hospital (Helsinki, Finland) or Tampere Heart Hospital,
Tampere University Hospital (Tampere, Finland). We assigned
48 patients to the RAA RNA sequencing arm and 6 patients
to the RNA sequencing data validation arm. Within the RNA
sequencing arm, 35 patients (35/48, 73%) underwent CABG
surgery, 8 patients (8/48, 17%) underwent aortic valve surgery,
and combined CABG and aortic valve surgery was performed
on 5 patients (5/48, 10%). According to invasive coronary
angiography (ICA), patients were categorized into IHD or non-
IHD groups. The IHD group (n = 40) included patients with
ICA occlusions, and contained patients who underwent CABG or
combined surgery. The non-IHD group (n= 8) included patients
with no ICA occlusions, and containing patients who underwent
isolated valvular surgery. All 6 patients in the validation
arm underwent CABG surgery and had ICA occlusions. We
used RAA RNAseq transcriptomes from donors (n = 429)
without heart disease from the GTEx biobank as the controls.
Causes of deaths among GTEx control patients were classified
according to the four-point Hardy Scale in order to exclude
cases with a cardiac background. Detailed patient demographic
characteristics are provided in Supplementary Table 1.
During cardiac surgery, a biopsy sample of the RAA was
collected from each patient. Tissue samples were collected at the
cannulation site, the insertion site of the venous line for the heart-
lung machine. Dissected biopsies were briefly washed in ice-cold
sterile saline, cut into 0.5 cm-thick tissue pieces, and immersed
into 3ml of RNAlater (Sigma Aldrich, Merck KGaA, Darmstadt,
Germany) to inactivate RNAses and stabilize RNA. Samples were
left to stabilize at +4◦C for 1 day and were thereafter stored
at −70◦C or below until processing. The RAA tissues of the
validation arm patients were collected into formalin for fixation
at +4◦C for 14 days, followed by storage in 70% ethanol until
processing for paraffin embedding.
Total RNA was isolated from RAA biopsies via initial
ice-cold tissue homogenization using a Precellys 24 tissue
homogenizer equipped with the Cryolys cooling option (Bertin
Technologies SAS,Montigny-le-Bretonneux, France) followed by
RNA isolation using combined QIAzol/chloroform extraction
and Qiagen RNeasy mini spin column purification according
to the manufacturer’s instructions (Qiagen, Venlo, Netherlands).
The sample RNA integrity number (RIN;mean 7.95± 0.55; range
7.1–9.0) and total quantity (mean 3069.55 ± 1141.08 ng; range
867.8–6855.0 ng) were evaluated in the Functional Genomics
Unit (FuGU, University of Helsinki, Helsinki, Finland). Isolated
total RNA was stored at −70◦C or below until sequencing. RNA
sequencing was performed by the BGI Group (Copenhagen,
Denmark). Ribosomal RNAwas removed using the Ribo-ZeroTM
Magnetic kit (Illumina Inc., San Diego, CA), and the samples
were sequenced using the BGI LncRNA-seq protocol with
Illumina HiSeq 4000 technology (100PE, BGI Group).
Collection of Patient Data
Cardiovascular disease and treatment-related clinical data were
collected from electronic healthcare records. Missing values
were retrieved and reanalyzed from the stored raw sequences,
including those from echocardiography, electrocardiography,
and angiography. Drug treatment data from the hospital
databases were meticulously recorded from 6-month pre- and
post-operative periods. To enable drug treatment comparisons,
we used the InnoLIMS Medical software (Innovatics Oy,
Helsinki, Finland) to categorize and standardize each treatment
according to its classification in the Anatomical Therapeutic
Chemical (ATC) classification system and by converting each
daily dosing regimen to the corresponding defined daily dose
(DDD, Finnish Medicines Agency, FIMEA, Helsinki, Finland
and the World Health Organization Collaborating Center
for Drug Statistics Methodology, Oslo, Norway). To capture
patients’ stable medication regimens unrelated to hospitalization,
treatments were recorded at 3 weeks preoperatively and 6
months post-operatively.
Data Analysis of RNA-Sequenced Data
Fastq files were trimmed using Trimmomatic v0.32 (7)
applying the following parameters: ILLUMINACLIP:<fasta
with adapters>:2:30:10 LEADING:3 TRAILING:3
SLIDINGWINDOW:4:15 MINLEN:36. Trimmed reads were
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mapped to the reference genome (EnsEMBL gene collection
v82) (8) using STAR v2.3.0 (9) with the following parameters:
–genomeLoad NoSharedMemory –readFilesCommand zcat
–outSAMattributes All –outSAMunmapped Within. For read
quantification, we used featureCounts (10) with the following
parameters: “-F” “GTF” “-t” “exon” “-g” “gene_id” “-O” “-T” “16”
“-a.” Gene counts from 429 healthy tissue samples were obtained
from the GTEx analysis release V8. For subsequent analyses,
only genes with an average logCPM >1 were considered. We
used R bioconductor’s package edgeR (11) to normalize the read
counts and test for differentially expressed genes. We performed
upper quartile normalization on the read counts, which were
fitted to a quasi-likelihood negative binomial generalized log-
linear model. In addition, we performed the quasi-likelihood
F-test using the glmQLFit and glmQLFtest functions. Finally,
differentially expressed genes were selected applying |logFC| >2
and FDR <0.05.
The RNA sequencing data is available from the Gene




We carried out functional enrichment analyses using IPA
software (Qiagen). Enriched pathways were selected using FDR
<0.05 for differentially expressed genes from ischemic, non-
ischemic, and healthy tissue samples. For the miRNA targets, we
selected enriched pathways applying p < 0.05. The functional
annotation of genes significantly downregulated or upregulated
across surgery benefit groups was extracted separately from the
diseases, and the functions tab for IPA, enriched diseases, and
functions were selected by excluding cancer-related results and
applying FDR <0.05.
miRNA Targets
miRNA targets were identified using Targetscan 7.2 (12).
Targetscan calculates context++ score for the complementary
site of miRNA by summing contributions from 14 features.
Some of the features are site type, 3′ UTR length, and the target
site abundance. The total context++ score is calculated for
a representative transcript by summing the context++ scores
for the sites to the representative miRNA. Many of the targets
for a specific miRNA are false positives in the Targetscan,
requiring a cutoff. Thus, targets were extracted using a cutoff
total context++ score <-0.8. We found that with a less stringent
cutoff, the number of targets increased greatly. This specific cutoff
was selected to extract high confidence targets.
Quantitative and Qualitative Patient
Categorizations
In order to quantitatively evaluate the complexity of coronary
artery obstructions, preoperative SYNTAX scores were calculated
for all patients. Patients were classified into three groups based on
their SYNTAX score values using cut-offs from the US/European
guidelines [low ≤22 (n = 34), intermediate 23–32 (n = 10),
and high score >33 (n = 4)] (13, 14). Moreover, information
on occlusion of proximal RCA was also collected in order to
perform subanalysis correlating proximal RCA occlusion and
gene expression of RAA. Major adverse cardiovascular and
cerebrovascular events (MACCE) relied on a four-point MACCE
score: death due to a cardiovascular reason, non-fatal stroke,
non-fatal myocardial infarction, and hospitalization due to heart
failure (HF). MACCE and mortality rates were recorded from a
5-year postoperative follow-up.
Surgery benefit was assessed by calculating the preoperative
and post-operative ejection fraction (EF). Preoperative EF was
evaluated within 1 month before surgery, and post-operative EF
was determined during a 3-month control visit. An EF change
was calculated (postoperative EF – preoperative EF), and patients
were divided into two groups according to the result: (a) good
benefit group (postoperative EF >10% better than preoperative
EF) and (b) poor benefit group (postoperative EF reduced >10%
compared to preoperative EF).
Validation
The six formalin-fixed AA samples for validation were paraffin-
embedded at the Tissue Preparation and Histochemistry
Unit (Faculty of Medicine, University of Helsinki, Finland).
Immunohistochemistry for FUT10 and CSRNP3 was performed
using standardized protocols at BioSiteHisto Ltd (Tampere,
Finland) and the primary antibodies validated in the Human
Protein Atlas project (www.proteinatlas.org, rabbit anti-human
CSRNP3 HPA017905 used here at dilution 1:75, and rabbit
anti-human FUT10 HPA053970 used here at dilution 1:50;
both from Sigma Aldrich, Merck KGaA, Darmstadt, Germany).
Staining was cross-validated against in-house human tissue
control sections. The immunostained RAA tissue sections
were scanned with the 3d-HISTECH Pannoramic MIDI II
imaging system using a x20 objective at 0.23 × 0.23 µm/pixel
resolution (3DHISTECH Ltd., Budapest, Hungary). For analysis,
serial non-overlapping images at ×20 magnification covering
each section were captured with the Pannoramic Viewer
software (3DHISTEC Ltd.). The analysis of the captured images
was carried out using the FiJI ImageJ software (15). The
image analysis macros are available upon request from the
corresponding author. Briefly, for each image, after background
subtraction, the color deconvolution algorithm to hematoxylin
(H) and diaminobenzidine (DAB) channels was utilized. The
DAB channel image was thresholded to the stain using the
automated default method based on the IsoData algorithm,
and the stain intensity was measured. For nuclear counting,
hematoxylin-positive nuclei (representing the total amount of
nuclei in the image) were counted from the H channel using the
particle-counting algorithm and compared with the thresholded
positively immunostained nuclei (stained nuclei) counted from
the DAB channel. The results of the densitometric image analysis
of the serial images for each sample were first averaged, and these
single values were then used for the further combined analysis
of results.
Statistical Analyses
Differentially expressed genes between phenotypic ischemic and
non-ischemic patient groups were identified by performing
permutation tests using gene TPMs (Transcripts per Million).
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Results from the permutation test were corrected using the
Benjamin-Hochberg FDR correction (FDR <0.05). Correlation
analyses relied on Pearson’s correlation comparing blood test
parameters and gene TPMs, for which we applied p < 0.05.
Genes associated with the SYNTAX score groups were identified
through a one-way ANOVA (p < 0.05) using the TPM values
for genes that were differentially expressed compared to GTEx.
For the clinical data, statistical differences in continuous variables
were calculated using the Kruskal-Wallis test (three groups) and
the Mann-Whitney U-test (two groups). Statistical differences in
categorical variables were calculated using Fisher’s exact test. We
considered p < 0.01 to denote statistical significance, and all p-
values were two-tailed. Clinical data were analyzed using SPSS
(IBM’s SPSS Statistics for Windows, version 25.0, IBM Corp.,
Armonk, NY).
RESULTS
Patients in the GTEx and non-IHD groups were younger (mean
age 56.26 years ± 10.74 and 59.75 ± 12.47, respectively) than
IHD patients (mean age 68.20 ± 8.28) (Figure 1A). While the
mean SYNTAX score was 0 in the non-IHD group, in the IHD
group it reached 18.29 ± 8.95. In addition, diabetes occurred
more frequently in the IHD group. Aortic cross-clamp times and
cardiopulmonary bypass (CPB) times were relatively longer in
the non-IHD group.
Preoperative medication in the IHD group reflected ischemic
disease, particularly the use of organic nitrates; no organic nitrate
use was recorded among non-IHD patients (Figure 1B). Post-
operatively, the dyspnea- and chest pain symptom-alleviating
effects of CABG surgery were reflected as an extinct use of organic
nitrates in IHD patients. Drug treatments were overall more
uniform following surgery. Postoperatively, statin treatment was
more common among IHD patients (p = 0.006). We detected
differences in postoperative complications or infections when
comparing groups. In total, three IHD patients, but no non-
IHD patients, were treated with antiarrhythmic medication
during the preoperative and postoperative periods. Overall, ACE
inhibitors and antithrombotics were used more during the post-
operative period.
DEGs Between IHD and Non-IHD
Compared to GTEx Database
A comparison of the gene expression profiles of the IHD
group and GTEx controls yielded 672 differentially expressed
genes (DEGs), 360 of which were upregulated and 312
downregulated (Figure 2A). Sirtuin signaling, epithelial adherens
junction signaling, and serine peptidase inhibitor Kazal type
1 (SPINK1) were significantly upregulated in the IHD group.
In contrast, agrin interactions and oxidative phosphorylation
were significantly downregulated (Figure 2D). In the non-
IHD vs. GTEx comparison, we identified 342 upregulated and
416 downregulated DEGs (Figure 2B). DEGs correlated with
inflammatory and immunological processes (Figure 2D). The
natriuretic peptide B (NPPB) coding gene was differentially
expressed in both the IHD (logFC −2.65, p < 0.001) and non-
IHD (logFC−4.08, p= 0.001) groups vs. the GTex group.
Differences Between IHD and Non-IHD
Groups
Comparison of IHD and non-IHD samples resulted
in 424 significantly upregulated and 500 significantly
downregulated genes (Figure 2C). DEGs were enriched in
oxidative phosphorylation, mitochondrial dysfunction, sirtuin
signaling, isoleucine degradation, and aspartate degradation
(Figures 2E,F). The two latter pathways strengthen previous
associations identified for branched-chain amino acids and
aspartate as metabolic contributors to IHD (16, 17). As such, our
results directly situate myocardial changes in these amino acid
pathways as the culprit in IHD.
The list of differentially expressed miRNAs, significant
downstream pathways, and functionally annotated targets of
these miRNAs from comparison of IHD and non-IHD is
shown in Figures 3A,B. We found a total of 13 differently
expressed miRNAs between groups (Figure 3A). The target
genes of these miRNAs are significantly enriched in cardiac
β-adrenergic signaling, role of NFAT in cardiac hypertrophy,
androgen signaling, and complement system pathways. A
three-layer subnetwork of interactions between miRNA, their
differentially expressed target genes, and their functions appears
in Figure 3C. Most of the miRNA targets in this subnetwork
are downregulated. These genes play a role in muscle cell death,
metabolizing pyruvic acid, fibroblast cell line proliferation, cell
invasion, synthesizing ATP, and degranulating neutrophils.
Clinical Associations to Preoperative
Condition
Ejection Fraction
We further divided IHD patients into two groups based on
a high (≥55%) or low (<55%) preoperative EF value and
clustered the genes accordingly (Figure 4A). Protocadherin
gamma family members (PCDHGs) exhibited higher expression
in the low preoperative EF group (EF <55%). The correlation
between PCDHGs and preoperative laboratory tests appear in
Figure 4B. PCDHGA1 and PCDHGA12 positively correlated
with preoperative NT-proBNP levels (Pearson R = 0.6, p =
0.04), while all PCDHGs negatively correlated with preoperative
EF values (Figure 4B). In addition, Figure 4C displays selected
PCDHGs and their expressions based on the preoperative EF
groups. Each selected PCDHG is highly expressed in patients in
the low EF group compared to the high EF group. These results
further strengthen the association of the PCDHG gene cluster
with cardiac dysfunction (18).
SYNTAX Score and Laboratory Measurements
We categorized the patients into three groups according to low,
intermediate, or high SYNTAX scores reflecting the level of
coronary artery obstruction complexity. All IHD patients except
one had obstructions also in the right coronary artery (RCA).
Total of 30 patients had occlusion in the proximal RCA, 7
patients in the mid RCA and 2 in the distal RCA. We identified
11 DEGs across the groups (ANOVA test, Figure 5A). Among
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FIGURE 1 | (A) Demographic characteristics of the study population. AMI, acute myocardial infarction; BMI, body mass index; COPD, chronic obstructive pulmonary
disease; CPB, cardiopulmonary bypass; MACCE, major adverse cardiovascular and cerebrovascular event; PCI, percutaneous coronary intervention. (B) Pre- and
post-operative medication use in the study groups. Color key representing the total use of medication (as log2 average DDD); bubble plot representing the percentage
of patients on medication indicated in study groups. DDD, defined daily dose.
them, CSRNP3 (Cysteine and Serine Rich Nuclear Protein 3) and
FUT10 (Fucosyltransferase 10) genes were common in DEGs in
the IHD vs. non-IHD groups (ANOVA p = 0.045 and p= 0.043;
FDR 0.036 and 0.030, respectively). Although the differential
expression of COX5A (Cytochrome C Oxidase Subunit 5A) and
ACSBG1 (Acyl-CoA Synthetase Bubblegum Family Member 1)
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FIGURE 2 | (A–C) Volcano plots providing an overview and the number of differentially expressed genes (DEGs). IHD vs. GTEx patients (A), non-IHD vs. GTEx
patients (B), and IHD vs. non-IHD patients (C). (D) DEG-related pathways between IHD and non-IHD vs. GTEx comparison. Major differences are highlighted in red,
with the color key showing the activation Z-score. The size of a balloon represents the –log(FDR) value. (E) P-values for the top five enriched pathways in IHD vs.
non-IHD group comparisons. (F) Number of DEGs in the top five enriched pathways IHD vs. non-IHD group comparisons.
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FIGURE 3 | (A) List of enriched miRNAs in IHD vs. non-IHD patients. Color key, log FC; bubble plot, number of targets. (B) List of pathways related to enriched
miRNAs. The bars express –log(p-value). (C) Differentially expressed downstream target genes and pathways related to hsa-mir-1254-1 and hsa-mir-6769a.
suggested IHD selectivity, with their expressions significantly
correlating with the SYNTAX scores (ANOVA p = 0.012 and p
= 0.030; FDR 0.060 and 0.085, respectively), this difference did
not emerge in the DEG comparison between the IHD compared
with non-IHD groups.
The associations between FUT10 and CSRNP3 and the
preoperative laboratory values appear in Figure 5B. FUT10
positively correlated with preoperative NT-proBNP levels
(Pearson R = 0.6; p = 0.03), whereas CSRNP3 positively
correlated with the blood CRP levels (Pearson R = 0.4; p =
0.03). The expressions of CSRNP3 and FUT10 were higher
in the high SYNTAX score category (Figure 5C), suggesting
that lower CSRNP3 and FUT10 expression levels reflect
milder or less complex coronary artery disease. Figures 5D,E
provide representative immunohistochemistry images of the
validation arm RAA samples with primary antibodies against
the FUT10 and CSRNP3 proteins. The results from the
immunohistochemistry analysis and box plots showing the
percentage of area staining for CSRNP3 and FUT10 compared
to the total sample area appear in Supplementary Figure 1.
We identified no statistically significant differences although
FUT10 protein expression presented with an increased tendency
in the high SYNTAX score group. Further analysis of the
FUT10 transcripts revealed the highest expression for the FUT10-
201 transcript (median TPM >2.5) in our study population
(Supplementary Figure 2) suggesting differential regulation of
alternate transcription. Results from RCA-occlusion subanalysis
are presented in Supplementary Figure 3.
Molecular Associations With Surgery
Benefit
IHD patients were divided into groups based on a positive or
negative benefit from surgery using the difference between pre-
and post-operative EF values. Positive or negative benefit was
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FIGURE 4 | (A) Heatmap showing a general overview of DEGs comparing the categorized EF groups in IHD patients. The heatmap color key expresses the Z-scores.
(B) Correlations between PCDHGs and preoperative EF and preoperative laboratory values. The size of the bubble indicates the p-value and the color key indicates
the Pearson R. (C) Correlations between preoperative EF and PCDHGs. EF, ejection fraction; PCDHG, protocadherin.
assigned if the magnitude of the EF difference was 10% or more.
Comparing the positive- and negative-benefit groups revealed a
total of 271DEGs. The clinical parameters among patients appear
in the upper panel of Figure 6. Despite the clinical heterogeneity
across patients, we identified 271 DEGs, among which 166
genes were downregulated and 105 genes were upregulated
in the negative-benefit group compared to the positive-benefit
group. The pathways associated with a surgical benefit (Figure 6)
emerged from a functional enrichment analysis. The degradation
of connective tissue (FDR = 0.031), cell migration (FDR =
0.034), and cell movement (FDR = 0.034) were upregulated
in the negative-benefit group. The pathways related to an
enlargement of the heart (FDR = 0.013), cardiomyopathy in
the heart ventricle (FDR = 0.019), and the organization of
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FIGURE 5 | (A) List of genes associated with SYNTAX score I. (B) FUT10 and CSRNP3 correlations with preoperative laboratory tests. The color key illustrates the
Pearson R and the size of the bubble indicates the p-value. (C) FUT10 and CSRNP3 expression in the SYNTAX score groups. (D,E) Representative CSRNP3 and
FUT10 stainings from the validation group.
mitochondria (FDR = 0.019) were upregulated in the positive-
benefit group. Cardiac status-related demographics of benefit
groups are presented in Supplementary Figure 4. Preoperative
EF and first postoperative day CK-MBm were higher in
the negative benefit group (Supplementary Figure 4A). No
clinical observations of perioperativemyocardial infarctions were
documented. The magnitude of the EF change was significantly
higher in the positive benefit group (Supplementary Figure 4).
Linearly correlated genes with an EF change appear in Figure 7.
The top three highest logFC genes comparing surgery benefit
classes were mir-181b (Pearson R= 0.362, p= 0.014),NAV2-AS4
(Pearson R=−0.327, p= 0.028), and SHD (Pearson R=−0.297,
p= 0.047).
DISCUSSION
In this study, we present analysis of an IHD-selective RAA
transcriptome and its relations to disease severity and
outcome from cardiac surgery. In addition, identification
of known IHD-associated pathways including changes in
energy metabolism, cell structure, and surface proteins
in the heart under pathological stress (16–21) further
validated the applicability of the RAA as a surrogate source
of information for enhancing our tissue-level understanding of
human IHD.
We utilized the SYNTAX score, calculated based on coronary
angiography, as a parameter for the complexity of coronary artery
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FIGURE 6 | Pathways associated with a positive and negative benefit from surgery according to EF change. The heatmap provides a visual overview of the
differences between two groups in terms of DEGs and clinically associated diseases, with color key representing the Z-score, and the top ten up and down regulated
pathways are listed with their log(FDR) values.
obstructions (22). Using ANOVA test, we detected significant
results in gene expression between the SYNTAX scores and two
IHD-associated DEGs. FUT10, or fucosyltransferase, catalyzes
the transfer of a fucose residue (23), promotes adipocyte
proliferation, and inhibits cell differentiation (24). Furthermore,
it is a regulator of cell proliferation, particularly in stem cell self-
renewal and in the maintenance of stem cell populations (25). In
addition, FUTs are hallmarks of M1 inflammatory macrophages,
and their expression, including that of FUT10, increases in
inflammatory lesions (26). Recently, the post-translational role
of FUTs in the glycosylation of immunoglobulins has garnered
increasing interest. FUT10 may serve as a possible target
for therapeutic intervention (27). Interestingly, one protein-
coding transcript (FUT10-201) incorporates a signal peptide, to
potentially produce a secreted protein (28). FUT10-201 transcript
emerged as the most highly expressed in our sequencing analysis
among sampled patients. This transcript and its coded (secreted)
protein represent interesting candidates as tissue-level and/or
circulating biomarkers for IHD. The expression of FUT10
resulted significant with SYNTAX scores and correlated with
preoperative NT-proBNP levels strengthening the correlation
between increasing fucosylation and decreasing cardiac function
in IHD.
CSRNP3 gene expression resulted significant with the
SYNTAX scores and correlated with preoperative CRP levels,
indicating its potential to serve as an IHD-specific marker.
CSRNP3 is expressed in the nucleus, carries transcription factor
activity (29), and links to apoptosis (30). Recently, CSRNP3
was identified as one of eight overlapping genes between
CD90pos MSCs (31) and the atherosclerosis associated gene
expression dataset of aorta and fat tissue, STARNET (32). Our
study further strengthens the association between CSRNP3 and
IHD/CAD, providing additional evidence of its cardiac tissue
IHD-specific expression. Subanalysis correlating gene expression
with proximal RCA occlusion strengthened the discovery of
HEY1—a transcriptional suppressor and an atrial NOTCH,
TGFbeta, and HIF1 pathway target gene—as an indicator of
cardiovascular functional reserve in myocardial ischemia.
Upregulated mir-1254, mir-6769, and mir-4459 and
their downstream target genes in IHD RAA showcase an
interregulating network related to inflammation and immune
regulation, cardiac hypertrophy, and adrenergic signaling.
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FIGURE 7 | (A) Top 10 genes linearly correlated with the change in EF following surgery. (B) Correlation heatmap of the genes mapped to a GO biological process.
Color key, correlation coefficient. (C) Correlation plots of the top three genes with the highest |logFC| between surgery benefit classes.
The hsa-mir-1254 and its target gene DBNL regulate cell
proliferation and immune responses (33–35), and increased
expression of DBNL has been reported in experimental
dilated cardiomyopathy (36). We found an IHD-associated
downregulation of two other hsa-mir-1254 target genes,
ALDOA (aldolase) and CLPP (caseinolytic mitochondrial matrix
peptidase proteolytic subunit). In hypertrophic cardiomyopathy,
reduced tissue expression of aldolase (37) and increased
plasma concentrations of secreted aldolase in cardiomyocyte-
derived exosomes have been reported (38, 39). In our data,
reduced ALDOA expression in RAA was associated with IHD,
suggesting a similar tissue-level regulation to that observed
in hypertrophic myocardium, possibly indicating a common
metabolic dysregulation in these diseases. Reduced expression
of CLPP, as found here to be IHD-associated, has also been
reported in knockout mice to decrease formation of cardiac
mitochondrial respiratory supercomplexes, T-cell activation,
and increased production of mediators of inflammation and
immunity contributing to inflammatory tissue injury (40,
41). Furthermore, reduced cardiac CLPP expression may
contribute to mitochondrial dysfunction and tissue injury
in IHD, but its actions in the heart seem to depend on
the disease background and require further elucidation (42).
The RAA IHD-associated miRNA hsa-mir-6769a regulates the
expression of synaptotagmin-7 (SYN7). Syn7 knock-out mice
present with increased cardiac inflammation and deposition
of collagen (43) suggesting that increased hsa-mir-6769a may
drive myocardial fibrosis, thus contributing to fibrosis in RAA.
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Another IHD-associated RAA miRNA found in our study, hsa-
mir-4459, has been reported to suppress inflammatory reactivity
and autophagy of vascular endothelial cells through inhibition
of its proinflammatory target gene LARP-1 (44) thereby possibly
also contributing to regulation of the inflammatory tissue
response in RAA under IHD.
We found IHD-associated reduced expression of the insulin-
like growth factor-1 receptor (IGR-1R) signaling effector
(45) hsa-mir-6815 in the RAA samples. Interestingly, it has
been shown that macrophages deficient of IGR-1R accelerate
atherosclerosis and increase atherosclerotic plaque vulnerability
(46) and that the hsa-mir-6815 response is activated under
hypoxia and coagulation (47). Taken together with our results,
these findings suggest that these RAA miRNAs can contribute to
the tissue level pathological process observed in IHD.
Our results suggest that IHD is associated with an increased
expression of transcriptional repressors, implying a complex
modulation of metabolic inflammation or macrophage
polarization through transcription factor activity and putative
aggravation through suppressing inflammatory repressors
(48). For example, KLF10 and KLF11 are tightly linked to
vascular inflammation, but also carry an anti-inflammatory
role in experimental disease models and in in vitro studies (49).
Our results associated KLF10 and KLF11 with IHD, thereby
indicating a further complexity to the transcriptional regulator
networks in the multimodal pathology of IHD. This agrees with
our findings of IHD-associated increases in the expression of
the inflammation-associated transcriptional activator RUNX1
(50) together with the transcription regulator MYEF2 shown to
modify RUNX1 function and target gene selectivity (51). Thus, it
seems feasible to assume a more elaborate and environmentally
sensitive mechanism for these factors in complex metabolic
diseases such as IHD (52).
We then analyzed the RAA DEGs that were associated with
the patients’ functional cardiac benefit from surgery. Despite
the complexity of categorical EF use, we were able to discover
DEGs that were related to absolute EF change and correlated with
surgery benefit without EF categorization. One such DEG, SHD,
encodes for an SH2 homology domain-containing protein SHD,
which interacts with key signaling phosphoprotein receptors such
as c-MET (53). Also the cis-natural antisense transcript NAV2-
AS4 significantly correlated with a benefit from surgery. NAV2
expresses in the heart (54), but its role has remained unspecified.
It has, however, been shown to regulate cell adhesion and neurite
outgrowth (55). Hsa-mir-181 expression levels significantly
negatively correlated with cardiac surgery benefit. Changes in
mir-181 expression have been associated with the early stages of
heart failure (56), regulating thrombin-induced endothelial cell
activation and dysfunction, arterial thrombosis pathology, and
promoting atherosclerosis (57). Moreover, diminished mir-181b
levels have correlated with the ability to remodel the extracellular
matrix affecting vascular stiffness via TGF-β signaling (58),
while circulating mir-181b levels have been associated with
diabetic cardiomyopathy (59). Due to mir-181’s ability to reflect
cardiac status, its expression represents a potential novel marker
for predicting cardiac surgery benefit. As associated with a
functional benefit from surgery, the expression of these DEGs
can serve as an indicator for the patient’s cardiac functional
recuperation reserve.
This study provides a rationale for the utilization of RAA
tissue RNA profiling in the search of potential IHD biomarkers.
We meticulously collected available clinical, imaging, and
laboratory data from electronic healthcare records as well
as documented patient drug treatments at a high resolution.
All analyses progressed according to clinical guidelines for
patient treatment and, thus, any study-guided analysis bias can
be eliminated. The classification of medications according to
their ATC class and the standardization of doses using DDD
conversions relying on the InnoLIMS Medical software platform
enabled us to compare drug treatments at various time points and
intervals. We also performed an initial immunohistochemical
validation of results for early preliminary confirmation of
our results.
Our study also has several limitations. The total number of
patients in the study and the relatively low number of non-
IHD patients limit our analytical power. Another limitation
lies in the retrospective collection of clinical data from
healthcare databases, possibly leading to incomplete coverage
and interobserver variability in the clinical measurements.
Lastly, immunohistochemical validations were performed on a
limited number of patient samples, with varying levels of IHD
according to the SYNTAX scores. Non-IHD patient samples or
samples from donors without cardiac disease were not used.
Thus, validation on a larger cohort is necessary. Our recently
initiated IHD-EPITRAN project (ClinicalTrials.gov identifier
NCT04533282) will address this limitation (60).
Based on their differential expression in the RAA tissue
of patients with or without IHD, we present here a specific
set of IHD-associated RNAs expressing significantly differently
when compared to coronary artery disease complexity, and
correlating with CRP, NT-proBNP, and surgery outcomes.
Specifically, FUT10 and CSRNP3 represent lucrative candidates
as IHD biomarkers.
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